Clinical Trial

CMR Prognostic Markers in Ischemic Heart Disease

Recruiting
View on ClinicalTrials.gov →
Summary
Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury. Cardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences. This multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values. Long-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.
Trial Details
NCT Number NCT07351825
Lead Sponsor Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborators: National Natural Science Foundation of China, Beijing Natural Science Foundation
Conditions Ischemic Heart Disease (IHD), Myocardial Infarction (MI)
Enrollment 1,000 participants
Start Date 2009-01
Primary Completion 2035-12 (estimated)
Study Completion 2035-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20